VALN רווחיות מכירות גולמית Valneva Corp

High R&D expenditures are creating financial pressure, which becomes evident on the chart through changes in gross margins. The value of 16.40 shows the current level of this parameter. However, the balanced vaccine portfolio of Valneva SE (VALN) minimizes risks, while its monopoly in the Lyme disease and Chikungunya drug segments strengthens its position. Stable plant utilization and line modernization guarantee production efficiency.
פילוחי מדדים מקיפים ואנליטיקה עבור Valneva SE (VALN)

Stable sales of niche vaccines driven by government contracts allow Valneva SE to effectively control production costs. Gross margin measures the profit share after deducting direct costs, reflecting the efficiency of the operating cycle and the issuer's pricing power; by analyzing the gross margin trend, an investor can assess the business model's resilience to cost inflation and hidden risks within supply chains.